Zylberberg B, Salat-Baroux J, Ravina J H, Dormont D, Amiel J P, Izrael V, Ekoundzola J R
J Gynecol Obstet Biol Reprod (Paris). 1985;14(4):515-21.
Sixteen patients with clinical primary inflammatory carcinoma of the breast were treated with initial immunochemotherapy from September 1974 to May 1977. This chemotherapy was an association of adriamycin, vincristine, fluorouracil, methotrexate, and melphalan. Thermographic cooling was taken as the criterion of operability. Chemotherapy was resumed after surgery up to a total of ten periods, and followed by a minimum one year chemotherapy. I-BCG-F Pasteur was used as immunotherapy and associated with the chemotherapy regimen. Five patients have died, four are alive with disease, and seven are free of disease at time of reporting. Median survival exceeds 90 months. Our data supports the conclusion that mastectomy combined with preoperative and postoperative immunochemotherapy may permit a better prognosis for inflammatory carcinoma of the breast: this benefit seems to be the consequence of adapting the length of initial chemotherapy to the data given by plate-thermography.
1974年9月至1977年5月，对16例临床诊断为原发性炎性乳腺癌的患者进行了初始免疫化疗。该化疗方案为阿霉素、长春新碱、氟尿嘧啶、甲氨蝶呤和苯丙氨酸氮芥联合应用。以热像图降温作为可手术性的标准。术后继续化疗，共进行10个疗程，随后进行至少一年的化疗。使用巴斯德I-BCG-F作为免疫疗法，并与化疗方案联合应用。5例患者死亡，4例带瘤生存，7例在报告时无病生存。中位生存期超过90个月。我们的数据支持以下结论：乳房切除术联合术前和术后免疫化疗可能使炎性乳腺癌的预后更好：这种益处似乎是由于根据热像图提供的数据调整初始化疗疗程的结果。
